SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGN-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGN-1 is under development for the treatment of liver cancer, head and neck cancer squamous cell carcinoma, non-hodgkin lymphoma, hodgkin lymphoma, skin cancer, sarcoma, pancreatic cancer, pseudomyxoma peritoneum (pseudomyxoma peritonei, PMP), squamous non-small cell carcinoma, cervical carcinoma, breast cancer, triple negative breast cancer, melanoma, head and neck cancer, ovarian cancer, small-cell lung cancer and hepatocellular carcinoma. The drug candidate is administered by intratumoral and intravenous routes. It acts by targeting amino acid metabolism.
It was also under development for the treatment of osteosarcoma and penile cancer.
For a complete picture of SGN-1’s drug-specific PTSR and LoA scores, buy the report here.